MarketLens

What Does Sarepta Therapeutics' Director Share Sale Signal to Investors

5 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Does Director Mitchell Tyson's Substantial Share Sale Mean for Photronics Investors

4 months ago

What Does Director Edman's Recent Sale Mean for TTMI Investors

4 months ago

What Does a CAO's Share Sale and Resignation Signal for Enhabit (EHAB) Investors

5 months ago

What Does Senator Peters' Corteva Sale Signal to Investors

3 months ago

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?

Ionis Pharmaceuticals director Hayden bought 20,000 shares for ~$1.1 million, raising his direct and indirect holdings by 34%, signaling insider confidence.

IONS

Stock News•2 weeks ago

What This Business First Insider Sale Signals After a 34% Stock Run

A director sold 20,000 shares at $31.79, totaling $635,800, cutting holdings by 8% after the stock's 34% run. The insider sale could signal reduced confidence at current valuation levels.

BFST

Stock News•1 months ago

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline

Savara executive sold 394,528 shares (~$2.24M) at ~$5.68 on June 22, 2026, representing 42.4% of holdings. The sale follows a 580,187-option exercise ahead of an FDA timeline.

SVRA

Stock News•2 months ago

Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?

Sarepta Therapeutics (SRPT) fell 19.9% since its last earnings report 30 days ago, as investors weighed results and the outlook for its gene therapy franchise.

SRPT